Asia Pacific Point Of Care Tb Drug Resistant Tb Testing Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The Asia Pacific point-of-care TB and drug-resistant TB testing market encompasses diagnostic technologies that enable rapid detection of Mycobacterium tuberculosis and its drug-resistant forms at or near the patient, bypassing the need for centralized laboratory infrastructure. The market was valued at approximately $57.35 billion in 2025 and is projected to grow at a compound annual growth rate of 8.5%, reflecting significant regional demand. Growth is concentrated in high-TB-burden countries where decentralized testing can dramatically improve case detection and treatment initiation timelines, particularly in remote and resource-limited settings.

• •The market spans molecular diagnostics and immunoassay-based point-of-care tests for both drug-sensitive and drug-resistant TB
• •Molecular assays, particularly nucleic acid amplification tests (NAAT), dominate due to their ability to detect TB and rifampicin resistance simultaneously within hours
• •Diagnostic laboratories, hospitals, and clinics represent the primary end-users across the region

The Asia Pacific region bears a disproportionate share of the global tuberculosis burden, with countries such as India, China, Indonesia, and the Philippines accounting for a significant portion of worldwide cases, including multidrug-resistant and extensively drug-resistant forms. Large-scale public-private partnerships involving the World Health Organization, national TB programs, and philanthropic organizations have increased funding for rapid diagnostic technologies, directly expanding access to point-of-care testing across urban and rural areas.

• •National and international TB elimination programs are prioritizing rapid diagnostics to meet global targets for case detection and treatment success
• •Advantages of point-of-care testing, including faster turnaround, reduced loss-to-follow-up, and improved treatment outcomes, are driving adoption over conventional sputum smear microscopy and culture
• •Growing awareness of drug-resistant TB and the urgent need for early detection to prevent transmission are fueling investment in advanced molecular testing platforms

Molecular diagnostics represent the largest and fastest-growing segment, propelled by the adoption of cartridge-based automated NAAT systems that deliver results in under two hours with high sensitivity and specificity for both TB and drug resistance. Immunoassays hold a smaller but steady market share, particularly in settings where molecular platforms are cost-prohibitive. By end-use, clinics and hospitals collectively represent the dominant application segment, while diagnostic laboratories remain critical for confirmatory testing and surveillance purposes.

• •Molecular diagnostics commands the majority of market share, with rapid NAAT platforms leading adoption in high-burden countries across the region
• •China and India are the largest national markets due to their massive TB caseloads, government-funded national programs, and expanding healthcare infrastructure
• •Southeast Asian nations including Indonesia, the Philippines, and Vietnam are experiencing particularly strong growth as screening and diagnostic capacity expands

What are the recent trends and outlook?

The market is being reshaped by the development of ultra-rapid molecular tests capable of delivering results in under 30 minutes, integrated digital connectivity for real-time surveillance and data reporting, and multiplex assays that simultaneously test for TB and multiple drug-resistance markers. These innovations align with growing emphasis on universal health coverage and digital health infrastructure investment across Asia Pacific governments. As the region moves toward 2030, the convergence of improved diagnostic technology, expanded healthcare access, and sustained public health funding is expected to sustain the 8.5% annual growth trajectory and deepen market penetration.

• •Next-generation point-of-care platforms featuring cartridge-based, instrument-free molecular testing are emerging to serve the most remote and resource-constrained settings
• •Integration of TB diagnostics with digital health systems enables real-time case notification, treatment monitoring, and antimicrobial resistance surveillance at the national level
• •Host-country manufacturing partnerships and technology transfer agreements are expected to lower costs and broaden access as the market scales